Literature DB >> 16108863

Antecedent hypoglycaemia attenuates vascular endothelial growth factor response to subsequent hypoglycaemia in healthy men.

V Merl1, A Peters, K M Oltmanns, W Kern, C Hubold, H L Fehm, J Born, B Schultes.   

Abstract

AIM: The plasma concentration of vascular endothelial growth factor (VEGF) has recently been shown to increase sharply in response to hypoglycaemia and, thus, has been proposed as having a role in hypoglycaemia counter-regulation. Many counter-regulatory hormones show a reduced response after antecedent hypoglycaemia. We therefore investigated whether this decrease in responsiveness with repetitive hypoglycaemia also pertains to VEGF.
METHODS: Three hypoglycaemic clamp experiments were performed on two consecutive days in 15 healthy men. VEGF response was assessed during the first and last hypoglycaemic period.
RESULTS: As expected, plasma VEGF concentrations rose markedly during the clamps (P < 0.001). The increase was distinctly blunted during the third (+13 +/- 8 pg/ml) as compared with the first (+54 +/- 18 pg/ml) hypoglycaemic clamp (P = 0.046).
CONCLUSION: This data confirms that circulating VEGF concentrations increase acutely during hypoglycaemia. Like the counter-regulatory hormones, the hypoglycaemia-induced rise in VEGF is attenuated after antecedent hypoglycaemia. The origin of increased systemic VEGF concentration during hypoglycaemia and its physiological role remains to be defined.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16108863     DOI: 10.1111/j.1464-5491.2005.01590.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  1 in total

1.  Evidence for a relationship between VEGF and BMI independent of insulin sensitivity by glucose clamp procedure in a homogenous group healthy young men.

Authors:  Michaela Loebig; Johanna Klement; André Schmoller; Simone Betz; Nicole Heuck; Ulrich Schweiger; Achim Peters; Bernd Schultes; Kerstin M Oltmanns
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.